莱普科技等4家企业上交所IPO审核状态变更为“中止(财报更新)”

Group 1: 莱普科技 (Lepu Technology) - Lepu Technology focuses on advanced precision laser technology and semiconductor innovation processes, primarily engaged in the R&D, production, and sales of high-end semiconductor equipment, along with related technical services [1] - The company's equipment has been successfully applied in cutting-edge applications such as advanced process 3D NAND Flash storage chips, advanced process DRAM storage chips, and SiC power chips [1] Group 2: 电建新能源 (China Electric Power Construction New Energy) - China Electric Power Construction New Energy specializes in the development, investment, operation, and management of wind and solar power projects within China, with a focus on expanding its wind and solar power business [2] - As of the end of the reporting period, the company has a total installed capacity of 21.2461 million kilowatts, including 9.8909 million kilowatts from wind power projects and 11.3552 million kilowatts from solar power projects [2] Group 3: 鞍石生物 (Anshi Biopharmaceutical) - Anshi Biopharmaceutical is an innovative biopharmaceutical company that has entered the commercialization stage, focusing on oncology and other diseases with significant unmet clinical needs [2] - The company has established a competitive and commercially viable multi-layered pipeline of innovative drugs targeting important tumor driver gene pathways such as MET, EGFR, and HER2 [2] Group 4: 泰诺麦博 (Tainuo Maibo) - Tainuo Maibo is an innovative biopharmaceutical company dedicated to blood product alternatives, with its core product, TNM002, being the first-in-class recombinant anti-tetanus toxin monoclonal antibody drug expected to be approved in China by February 2025 [3] - TNM002 has been recognized as a breakthrough therapy by China's CDE and included in the priority review process, marking a significant innovation in the field of infection prevention [3] - Another core product, TNM001, is a potential long-acting monoclonal antibody for RSV prevention in infants, currently undergoing Phase III clinical trials [3]